← Dashboard

Compliance Alert: ATTR-CM Quick Takes: From Early Indicators (001) - Monitoring

Configure Methodology
80
Lower Risk
This HCP Educational video is within acceptable compliance thresholds.

Analysis of this 225s HCP Educational video identified 1 enforcement pattern, primarily Fair Balance. Patterns span Fair Balance, previously cited in FABHALTA, Vyvgart Hytrulo (x2), Wegovy. Benefit-to-risk presentation ratio is 8.7:1.

Recommended action: Flag for next MLR cycle: Benefit-to-risk presentation balance requires attention. Ensure risk information receives comparable prominence, duration, and audio/visual treatment.

ATTR-CM Quick Takes: From Early Indicators (001) - Monitoring | Attruby| BridgeBio Pharma, Inc. | HCP Educational
DOC-2025-001244 Mar 10, 2026
80
Master
--
Visual
N/A
84
Efficacy
40%
HCP thresholds
58
Fair Balance
10%
HCP thresholds
85
Adeq Prov
10%
HCP thresholds
--
Lifecycle
10%
Video Timeline
Risk disclosure: 112.0s – 135.1s (23.1s of 224.9s total — 10.3% of ad)
Risk Window
0s56s112s169s225s
No visual distractions detected
Risk Window?The portion of the ad where side effects and safety warnings are narrated. Distracting visuals during this window are an FDA enforcement priority.
Patterns Detected (1)
Each pattern below is a known FDA enforcement concern, identified by matching this ad against 14 violation types from 34 FDA warning letters
Pattern Dimension Score Evidence CFR
Benefit vs. Risk Time Imbalance
Significantly more time spent on benefits than on risks
 Fair Balance 58 1 metric 21 CFR 202.1(e)(3)(iii) ▶

Recommendations

high
Flag for next MLR cycle: Benefit-to-risk presentation balance requires attention. Ensure risk information receives comparable prominence, duration, and audio/visual treatment.
▶ Full Video Preview 3:45 · HCP Educational
ATTR-CM Quick Takes: From Early Indicators (001) - Monitoring
HCP Educational
Duration: 3:45 Alert: ATT-2026-0017
Veeva PromoMats Details
Synthetic data for demonstration purposes. In production, this section is populated from Veeva PromoMats via API integration.
Document ID
DOC-2025-001244
Status
Approved for Distribution
Version
1.0
Content Type
Celebrity Endorsement
MLR Review
Jun 18, 2025
Next Review Due
May 20, 2026 (70d)
Talent Expiration
Dec 1, 2025 (Expired)
Music License
Jun 1, 2026 (82d)

Powered by cQuenced